FIELD: medicine.
SUBSTANCE: invention concerns identification of non-peptide inhibitors of cathepsine G. The given substances immediately inhibit biological functions of the target protein. The cathepsine G-inhibiting aptamers consist of linear DNA-sequences or polynucleotide sequences which have length of a chain at least of 60 nucleotides and not subjected to effective pairing of the bases.
EFFECT: offered aptamers are characterised by high selectivity and can be used at treatment and preventive maintenance of inflammatory processes and procoagulant conditions.
7 cl, 3 dwg, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| NUCLEIC ACID COMPOUNDS FOR BINDING GROWTH DIFFERENTIATION FACTOR 11 | 2015 |
|
RU2708170C2 |
| APTAMERIC THERAPEUTIC AGENTS APPLICABLE FOR TREATING COMPLEMENT-RELATED DISORDERS | 2006 |
|
RU2406507C2 |
| COMPLEMENT-BINDING APTAMERS AND C5 AGENTS APPLICABLE FOR TREATING OCULAR DISORDERS | 2007 |
|
RU2477137C2 |
| METHOD TO SEPARATE SPERMATOZOA AND APPLIED COMPOSITIONS, CONTAINING APTAMERS OR SEQUENCES OF NUCLEIC ACIDS | 2007 |
|
RU2475539C2 |
| DNA APTAMER SEQUENCE BINDING TO PEPTIDOGLYCAN-ASSOCIATED LIPOPROTEIN LEGIONELLA PNEUMOPHILA | 2019 |
|
RU2737829C1 |
| MIDKINE APTAMER AND USE THEREOF | 2007 |
|
RU2460794C2 |
| OLIGONUCLEOTIDES CONTAINING MODIFIED NUCLEOSIDES | 2017 |
|
RU2763470C2 |
| METHOD FOR OBTAINING THERAPEUTIC AGENT FOR CURING OF TICK-BORNE ENCEPHALITIS | 2012 |
|
RU2501862C1 |
| DNA SEQUENCE USED AS PROBE FOR PROVIDING MAXIMUM RATIO OF "SIGNAL/BACKGROUND" IN TEST SYSTEMS BASED ON IMMUNO-PCR | 2014 |
|
RU2566550C1 |
| MODIFIERS OF GLYCOPROTEIN VI REPRESENTING NUCLEIC ACID | 2010 |
|
RU2571660C2 |
